Acasti to Present at The Annual Roth Conference and Grants Incentive Stock Options
2012年3月6日 - 10:00PM
Acasti Pharma Inc. ("Acasti") (TSX-V:APO), a Neptune Technologies
& Bioressources Inc. ("Neptune") subsidiary, announces it will
be presenting at the 24th Annual Roth Conference and that it has
granted incentive stock options.
Acasti at The 24th Annual Roth Conference:
Monday, March 12, 2012 4:30 PM, Pacific Time Ritz Carlton Hotel,
Dana Point, California Speaker : Harlan Waksal, M.D., Executive
Vice-President, Business & Scientific Affairs
The 24th Annual Roth Conference is taking place in California
from March 11 to 14, 2012. Over 400 companies selected by Roth
Capital Partners will be represented at the conference and the
organizers expect over 1000 buy-side investors. This event is
designed to provide investors with a unique opportunity to gain
insight into small and mid-cap growth companies across a variety of
sectors.
A webcast of the presentation will be available on the Acasti
website at www.acastipharma.com shortly after the presentation.
Incentive Stock Options
As of March 5th, 2012, the Board of Directors, as part of its
annual review of direct and indirect remunerations, decided to
grant a total of 2,105,000 incentive stock options of Acasti to
employees, executives officers and directors. Acasti incentive
stock options have an exercise price of $2 and a 5 year
maturity. Insiders have been granted a total of 1,450,000
Acasti incentive stock options.
The options were granted subject to provisions of the Company's
stock option plan which was approved by shareholders in June 2011,
and subject to the TSX policies and the applicable securities
laws.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the major
component of cell membranes and are essential for all vital cell
processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular and cardiometabolic
conditions within the over-the-counter, medical food and
prescription drug markets.
About Neptune Technologies & Bioressources
Inc. (Nasdaq:NEPT) (TSX-V:NTB)
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995 and Canadian securities laws. Such forward-looking
statements involve known and unknown risks, uncertainties, and
other unknown factors that could cause the actual results of the
Company to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. In addition to statements which explicitly describe
such risks and uncertainties, readers are urged to consider
statements labeled with the terms "believes," "belief," "expects,"
"intends," "anticipates," "will," or "plans" to be uncertain and
forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that
are described from time to time in the Company's reports filed with
the Securities and Exchange Commission and the Canadian securities
commissions.
CONTACT: Acasti Contact:
Tina Sampalis
President
+1.450.686.4555
t.sampalis@acastipharma.com
www.acastipharma.com
Xavier Harland
Chief Financial Officer
+1.450.687.2262
x.harland@acastipharma.com
Howard Group Contact:
Dave Burwell
+1.888.221.0915
dave@howardgroupinc.com
www.howardgroupinc.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024